Neda Stjepanovic

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Neda Stjepanovic, Leticia Moreira, Fátima Carneiro et al. · Annals of Oncology · 2019 · 238 citations · Full text

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy et al. · Journal for ImmunoTherapy of Cancer · 2020 · 66 citations · Full text

Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?

Alejandro Moles‐Fernández, Laura Duran-Lozano, Gemma Montalban et al. · Frontiers in Genetics · 2018 · 64 citations · Full text

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

Scott Antonia, Sang‐We Kim, Alexander I. Spira et al. · Journal of Clinical Oncology · 2016 · 47 citations

Immunology, Immunoediting, Immunotherapeutics +17

Screening of <i>BRCA1/2</i> deep intronic regions by targeted gene sequencing identifies the first germline <i>BRCA1</i> variant causing pseudoexon activation in a patient with breast/ovarian cancer

Gemma Montalban, Sandra Bonache, Alejandro Moles‐Fernández et al. · Journal of Medical Genetics · 2018 · 39 citations